Center-Authored Papers

Filters: Author is Bennett, John M  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM et al..  2005.  Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.. Blood. 105(12):4576-82. Abstract
G
Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE et al..  2017.  Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(1):60-87. Abstract
Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD et al..  2011.  Myelodysplastic syndromes.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(1):30-56. Abstract
Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT et al..  2015.  Myelodysplastic syndromes, version 2.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(3):261-72. Abstract
Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G et al..  2013.  Myelodysplastic syndromes: clinical practice guidelines in oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(7):838-74. Abstract
L
Lucas DM, Ruppert AS, Lozanski G, Dewald GW, Lozanski A, Claus R, Plass C, Flinn IW, Neuberg DS, Paietta EM et al..  2015.  Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergr. Leukemia & lymphoma. 56(11):3031-3037. Abstract
O
Oliansky DM, Antin JH, Bennett JM, Deeg HJ, Engelhardt C, Heptinstall KV, DeLima M, Gore SD, Potts RG, Silverman LR et al..  2009.  The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(2):137-72. Abstract
S
Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, Dewald G, Bennett JM, Paietta EM, Byrd JC et al..  2011.  Incidence of Therapy-related Myeloid Neoplasia after Initial Therapy for CLL with Fludarabine-Cyclophosphamide versus Fludarabine: Long-Term Follow-up of US Intergroup Study E2997.. Blood. 118(3):3525-3527. Abstract
T
Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH et al..  2010.  Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 116(25):5650-9. Abstract
Tefferi A, Kantarjian H, Rajkumar VS, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC et al..  2015.  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.. Mayo Clinic proceedings.